BICO Group AB (publ) (CLLKF)
- Previous Close
5.5000 - Open
5.5000 - Bid 2.9000 x 38500
- Ask 3.4100 x 29200
- Day's Range
5.5000 - 5.5000 - 52 Week Range
3.0100 - 6.9000 - Volume
140 - Avg. Volume
67 - Market Cap (intraday)
219.708M - Beta (5Y Monthly) 2.38
- PE Ratio (TTM)
-- - EPS (TTM)
-1.9400 - Earnings Date Nov 26, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
BICO Group AB (publ) operates as a bioconvergence company in North America, Europe, Asia, and internationally. It operates through three segments: Bioprinting, Biosciences, and Bioautomation. The Bioprinting segment offers products, solutions, and services that enable proliferation of 3D cell culture and 3D printing. The Biosciences segment provides instruments that enable the handling of cells and rare samples, and rapid transfer of liquids and reagents, as well as downstream analysis platforms. The Bioautomation segment offers end-to-end products and services in precision dispensing, advanced sample preparation, multiplex analysis and assay miniaturization, diagnostic and medical device manufacturing for life science and diagnostic industries. It primarily serves medical, pharmaceutical, and cosmetic industries. The company offers its products through sales organizations, as well as through an extensive distributor network. The company was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. BICO Group AB (publ) was incorporated in 2016 and is headquartered in Gothenburg, Sweden.
www.bico.comRecent News: CLLKF
View MorePerformance Overview: CLLKF
Trailing total returns as of 11/21/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CLLKF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLLKF
View MoreValuation Measures
Market Cap
221.69M
Enterprise Value
338.04M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.06
Price/Book (mrq)
0.79
Enterprise Value/Revenue
1.63
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-63.87%
Return on Assets (ttm)
-3.05%
Return on Equity (ttm)
-33.30%
Revenue (ttm)
2.42B
Net Income Avi to Common (ttm)
-1.5B
Diluted EPS (ttm)
-1.9400
Balance Sheet and Cash Flow
Total Cash (mrq)
687.6M
Total Debt/Equity (mrq)
65.85%
Levered Free Cash Flow (ttm)
333.91M